611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Basic InformationLatest News
General, Central Obesity Linked to Specific Breast Cancer RiskProstate Cancer Symptoms Aren't Always ObviousCancer Treatment Can Affect Your Food PreferencesExpected Burden of Lung Cancer High for People Living With HIVNew Link Seen Between Gene Fusion and Bladder CancerSkin Cancer Prevention Strategies Needed in Work SettingsFDA Approves First Biosimilar Drug for CancerAliqopa Approved for Follicular LymphomaFibrous Dysplasia Associated With Increased Breast Cancer RiskU.S. Cancer Death Rate Continues to FallAACR Releases 2017 Cancer Progress ReportUSPSTF Backs Cervical Cancer Screening With Cytology or hrHPVMultivitamin Use May Cut Risk of Chemo-Induced NeuropathySurgeons Play Big Role in Women's Choices for Breast Cancer CareDabrafenib, Trametinib Beneficial in Resected MelanomaNew Guideline Aims to Help Doctors Diagnose Head, Neck MassesWidening Waistlines May Raise Women's Cancer RiskAdjuvant Nivolumab Tops Ipilimumab in MelanomaHPV Test Alone OK for Cervical Cancer Screening Over 30: Expert PanelCancer Drugs' High Prices Not Justified by Cost of Development, Study ContendsMedian Cost of Cancer Drug Development $648.0 MillionManaging Pain Can Be a Puzzle After Breast CancerImmune-Focused Drug May Be New Weapon Against Advanced MelanomaObamacare Paid Off for Poorer Cancer PatientsStrong Evidence for Healthy Lifestyle Reducing CRC RiskHere's the Recipe to Keep Colon Cancer at BayCRC Tumor Cells Exposed to Gut Bacteria Express ChemokinesUniversal Sequencing of Cancer Genes Ups Mutation DetectionMailed Invitations Increase CRC Screening CompletionInactivated Vaccinia Virus Shows Promise Against Advanced Cancer'Cancer Pen' Could Help Surgeons Spot Tumor Cells in SecondsCould the Zika Virus Help Battle a Deadly Brain Cancer?New Research Finds Value in PSA TestingHealth Tip: Diet and Activity May Help Prevent CancerFDA OKs Return of Once-Withdrawn Leukemia DrugLow Tumor Growth Rates During Active Surveillance of Thyroid CAScience Weighs in On How Fat Raises Cancer RiskFirst Gene Therapy Approved in U.S.Options Available for Estrogen Depletion After Breast CancerMoles Not Most Likely Spot for MelanomasAndrogen-Deprivation Therapy May Carry Cardiovascular RisksComputed Tomography Useful for Staging Head, Neck MelanomaCommon Treatment for Early Prostate Cancer May Carry Heart RiskCould Common Vitamin Supplements Raise Lung Cancer Risk?Females Show Better Response to CRT in Esophageal CancerOutdoor Nighttime Light Exposure Linked to Breast Cancer RiskArsenic Levels Higher in Patients With Nonmelanoma Skin CancersRadioiodine Therapy for Thyroid Cancer Doesn't Up Stroke RiskOne-Quarter With Early Breast Cancer Strongly Considers CPMFDA Approves New Treatment for Acute Lymphoblastic Leukemia
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemo Drug May Buy Time for Those With Bile Duct Cancer

HealthDay News
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds.

People with bile duct cancer who received the medication lived for an average of about 17 months longer than those who didn't take it, the researchers found. Based on the findings, the study authors suggested that Xeloda should be given routinely to patients with this disease.

Bile duct cancer -- which occurs in an area that connects the liver, gallbladder and the small intestine -- is rare and aggressive. It affects an estimated 8,000 people in the United States each year, according to the American Cancer Society.

A statement from Cancer Research UK, which funded the new study, said it's difficult to study treatments for bile duct cancer because so few patients are available to take part in clinical trials.

For the study, researchers gave capecitabine (Xeloda) to about half of 450 bile duct cancer patients who underwent surgery. The other half underwent surgery but didn't get the drug.

The average survival after surgery for those who took the drug was 53 months compared to 36 months for those who only had surgery, the findings showed.

"While rare, bile duct cancer is difficult to treat and until recently there has been very little progress in treating the disease," said lead researcher John Primrose, of the University of Southampton in the United Kingdom.

"Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects," he said in a Cancer Research UK news release.

The findings are to be presented at the American Society of Clinical Oncology's annual meeting in Chicago in June. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.

More information

For more about bile duct cancer, visit the American Cancer Society.